Phase 3 N=529 Fixed-Dose Trial in Early Parkinson's Disease (PD)
Parkinson Disease
Primary: Change From Baseline in the MDS-UPDRS Parts II and III Combined Score — 1.8; -9.7; -10.2 score on a scale — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=172 Muscle Relaxation for Pediatric Adenotonsillectomy
Tonsillectomy
Primary: Cumulative Intra- and Postoperative Opioid Consumption — 0.209; 0.188 IV morphine milligram equivalent/kg — p=0.123
Phase 3 N=120 A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
Hemophilia A
Primary: Number of Participants With FVIII Inhibitor Development — 11 Participants
Phase 2 N=106 Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
Metastatic Cancer
Primary: Objective Response Rate — 11; 6 Participants
Phase 2 N=327 A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
Alzheimer Disease
Primary: Change From Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population) — -8.39; -13.27; -10.07 score on…
N/A N=94 Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients
Breast Carcinoma
Primary: Incidence of Chemotherapy Induced Peripheral Neuropathy (CIPN) — 41; 30; 25 Participants
Phase 2 N=1,015 Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
Pneumococcal Vaccines
Primary: Percentage of Subjects Reporting Solicited Local Reactions Within 7 Days After Vaccination (Redness, Swelling, and Pain at Injection Site) in Each Age Group — 66.8…
Phase 2 N=174 Mindfulness-based Cognitive Coping for ADRD Caregivers
Caregiver Stress
Primary: Center for Epidemiological Studies Depression Scale — 17.1; 21.98 score on a scale
N/A N=222 Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
Sickle Cell Disease · Chronic Kidney Diseases · Systemic Lupus Erythematosus
Primary: Change in Self-management as Measured by the Partners in Health Scale — 6.7; 6.5; 6.8; 6.6 score on a scale — p=0.0034
Phase 3 N=9 Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
Neonatal Sepsis
Primary: Number of Patients With Adverse Events (AEs) — 3; 3; 0; 0 Participants
N/A N=72 Metacognitive-Strategy Training in Sub-Acute Stroke
Stroke
Primary: Canadian Occupational Performance Measure (COPM) — 3.77; 3.87 score on a scale — p=.693
Phase 2 N=77 Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
Nonproliferative Diabetic Retinopathy
Primary: Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 36 — 5.0; 0; 4.8 percentage of subjects
N/A N=8,370 Dose Reduction and Discontinuation With Anti-Fibrotic Medications
Idiopathic Pulmonary Fibrosis
Primary: Number of Patients With Dose Reduction and/or Temporary Dose Reduction (Sub-optimal Dose) by 12 Months — 301; 373 Participants
N/A N=40 Evaluating an mHealth Intervention for Reducing Alcohol Use Among Adolescent and Young Adult Cancer Survivors
Cancer · Alcohol Use
Primary: Percent of Eligible Participants Enrolling in the Study — 66.7 percentage of eligible who enrolled
N/A N=355 Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening
Cancer
Primary: Abstracted Chart-level Accuracy — 76.10; 71.48; 59.92 % of elements correctly abstracted — p=<0.001